Clinical trials: Attention Deficit Disorder Without Hyperactivity
- Condition Attention Deficit Disorder Without Hyperactivity
- Funder type Industry (pharma, biotech, devices)
Attention Deficit Hyperactivity Disorder
PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations
This is PART A of a 2-part, 6-week, double-blind, dose-optimization, parallel-group study in children and adolescents (ages 6-17 years) with ADHD with and without CNVs in specific genes implicated in glutamatergic signaling and…
- Trial name
- NCT03265119
- Testing
- AEVI-001
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
ADHD - Combined Type, ADHD Predominantly Inattentive Type
NeuroTrainer Cognitive Training For Academic Focus
This clinical trial aims to evaluate the feasibility and efficacy of NeuroTrainer cognitive training in improving attentional and executive control functions in students with and without attention-related difficulties.
- Conditions
- ADHD - Combined Type, ADHD Predominantly Inattentive Type, ADHD, Predominantly Hyperactive - Impulsive
- Trial name
- NCT06512974
- Testing
- NeuroTrainer
- Where
- 3 sites in United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- NeuroTrainer
ADHD, PMS
Prevalence of Lidocaine Ineffectiveness in Adults With and Without ADHD
This work will assess the prevalence in the general population of the ineffectiveness of the anesthetic Lidocaine compared to males with ADHD and females with ADHD with or without PMS.
- Trial name
- NCT03676725
- Testing
- Lidocaine gel
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- PhenoSolve, LLC
Attention Deficit Hyperactivity Disorder
A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations
This is a non-interventional study in children and adolescents (ages 6-17 years) with attention deficit hyperactivity disorder (ADHD) to assess CNVs in specific genes involved in glutamatergic signaling and neuronal connectivity.
- Trial name
- NCT03233867
- Where
- United States
- Volunteers
- 2,503 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Attention Deficit Disorder With Hyperactivity
Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
This study aims to assess the effectiveness of atomoxetine on psychosocial functioning and emotional well being of children and adolescents with ADHD and to evaluate whether and in what measure the presence of comorbid conditions…
- Trial name
- NCT00320528
- Testing
- atomoxetine
- Where
- 20 sites in Italy
- Volunteers
- 269 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations
This is PART B of a 2-part, 6-week, double-blind, dose-optimization, parallel-group study in children and adolescents (ages 6-17 years) with ADHD with and without CNVs in specific genes implicated in glutamatergic signaling and…
- Trial name
- NCT03609619
- Testing
- AEVI-001
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company